Innoviva, Inc. (INVA) News
Follow Innoviva, Inc. (INVA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Innoviva Coverage Assumed by Oppenheimer at Outperform
Ratings actions from Benzinga: GMT) Innoviva Price Target Announced at $35.00/Share by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:24 PM UTC
L
INVA: Specialty therapeutics and innovative drug delivery drive growth, with resilient royalty streams funding expansion
Specialty therapeutics revenue exceeded $200 million, driven by XACDURO and GIAPREZA, with strong U.S. and ex-U.S. growth. Nortiva's LYNX platform targets once-monthly oral contraceptives, supported by the Gates Foundati
EQUITY | Sep 10, 2026, 01:40 PM UTC
L
INVA: Specialty therapeutics and innovative drug delivery drive growth, backed by stable royalties
Specialty therapeutics revenue exceeded $200 million, driven by strong growth in XACDURO and GIAPREZA, with global expansion through partnerships. Nortiva's LYNX platform targets once-monthly dosing, starting with a cont
EQUITY | Sep 10, 2026, 01:02 PM UTC
L
INVA - Innoviva to Participate in Upcoming Investor Conferences
INVA - Innoviva to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:08 PM UTC
L
Innoviva to participate in upcoming investor conferences
Innoviva says it will participate in upcoming investor conferences. The company describes its diversified biopharmaceutical focus, including a royalties portfolio and critical care and infectious disease platform.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
INVA Therapies Named Finalists for Prix Galien USA Award
Innoviva Specialty Therapeutics' XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA Best Pharmaceutical Product Award
EQUITY | Aug 11, 2026, 08:12 PM UTC
L
Innoviva Therapies Named Finalists
Innoviva's XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA award
EQUITY | Aug 11, 2026, 08:05 PM UTC
L
INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
EARNINGS | Aug 05, 2026, 08:17 PM UTC